Evidence types
Phase 3 clinical trial articles covering late-stage treatment evidence, safety, effectiveness, and regulatory context in IBD. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
Page 1 of 4 · 158 articles
People hospitalized with acute severe ulcerative colitis face a high risk of steroid failure and need for rescue therapy or colectomy. This trial explores whether adding the JAK inhibitor tofacitinib to corticosteroids...
Long-term extension studies collect additional safety and tolerability information and can provide continued access to an investigational drug for people who were in the parent trials.
Long-term Phase 3 extension data suggest guselkumab (Tremfya) can sustain clinical and endoscopic remission through three years for some patients with Crohn’s disease.
Reports effectiveness and safety of risankizumab specifically in East Asian participants from global phase 2b/3 UC trials, which may inform regional applicability of trial results for people with moderate-to-severe...
Perianal fistulas are a challenging complication of Crohn’s disease with limited effective options; a phase 3 trial reports that guselkumab improved fistula remission rates through 48 weeks, which could offer a new...
New Phase III data on guselkumab are directly relevant because they report long-term (3-year) maintenance results for Crohn’s disease and one-year fistula outcomes for people with perianal disease — areas that affect...
Children with Crohn’s disease may have vitamin D deficiency and a theoretical link between vitamin D levels and relapse risk; this trial tested whether adding high‑dose vitamin D3 at diagnosis could lower relapses and...
Cure8 found this source from chicagobusiness.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full...
The study focuses on children newly diagnosed with Crohn's disease who start anti-TNF treatment and aims to identify biological and clinical markers tied to complete intestinal healing after one year; results could help...
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Ulcerative colitis and Research and clinical trials. The original article is from Przegla̜d Gastroenterologiczny.
Cure8 could only read part of this source from finance.yahoo.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
Positive Phase 3 pediatric data could expand access to Omvoh for children with ulcerative colitis and change treatment options. That matters to families, clinicians, and patients using or considering biologic therapy.
Narrowing (stenosis) can cause obstructive symptoms and often leads to surgery; evidence that a biologic—guselkumab—may improve non-passable stenosis and reduce fibrosis-associated biology could affect treatment planning...
Perianal fistulas are a common, debilitating complication of Crohn’s disease; longer-term data on treatments that can produce durable fistula remission are directly relevant to patients and clinicians managing this...
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
These Phase 3 results suggest guselkumab (TREMFYA) may provide durable clinical and endoscopic benefit through three years for adults with moderate to severe Crohn’s disease and may help with perianal fistula...
Cure8 found this source from pluang.com, but the page could not be read reliably yet. It is tagged for Mirikizumab, IL-23 inhibitor, and Research and clinical trials. Open the original article for the full details.
A Phase 3 study is testing whether upadacitinib is safe and effective for children with moderate-to-severe Crohn's disease who have not responded to or cannot take other therapies. Positive results could expand treatment...
Company-reported one-year results suggest mirikizumab (Omvoh), an IL-23p19 inhibitor, can achieve multi-dimensional treatment goals including symptom control, quality-of-life improvement, and steroid-free deep remission...
Deep remission is an emerging treatment target in Crohn’s disease that combines symptoms and objective measures. A meaningful proportion of patients in VIVID-1 achieved corticosteroid-free deep remission with mirikizumab...
Phase 3 results suggest mirikizumab (Omvoh) can produce sustained, steroid-free remission-related outcomes at one year in both ulcerative colitis and Crohn’s disease, including in some patients who previously failed...
New one-year trial analyses suggest mirikizumab (Omvoh) may help more people with moderate-to-severe ulcerative colitis or Crohn’s disease reach combined clinical and endoscopic goals and reduce steroid dependence.
These results suggest mirikizumab can achieve multiple treatment goals at once — symptoms, objective inflammation measures, and steroid-free status — outcomes that matter to people with IBD because they reflect both...
Late-stage (Phase 3) AFFIRM data for subcutaneous Skyrizi in Crohn’s disease are being presented publicly — that could lead to new treatment options if regulators approve expanded indications, and it influences...
Positive phase 3 results for a subcutaneous risankizumab induction regimen may expand access to an IL‑23 p19 therapy option that avoids IV induction and showed strong short-term remission and endoscopic response rates in...
Positive Phase 3 data for Skyrizi in Crohn’s could affect treatment options and access if regulators expand the drug’s label and insurers update coverage; for patients and clinicians it may signal an additional biologic...
Phase III AFFIRM results suggest a subcutaneous risankizumab regimen may increase endoscopic remission in Crohn’s disease, which matters for patients and clinicians weighing biologic options and for regulatory approval...
A Phase 3 positive result for subcutaneous SKYRIZI could expand treatment options for people with Crohn’s disease by offering a more convenient dosing route and may affect how available drugs like Rinvoq are used. It...
New Phase 3 data suggest subcutaneous risankizumab (Skyrizi) can achieve meaningful endoscopic remission and ulcer-free endoscopy rates in adults with active Crohn's disease, including higher responses in patients...
Endoscopic remission (visual healing) is linked to better long-term outcomes in Crohn's disease. An approved subcutaneous induction option could make risankizumab easier to use outside infusion settings.
Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.
A new subcutaneous option for risankizumab (SKYRIZI) showed higher rates of endoscopic remission and ulcer-free endoscopy versus placebo in a Phase 3 Crohn's disease trial, which could expand at-home biologic options if...
Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Risankizumab, and IL-23 inhibitor. Open the original article for the full details.
New Phase 3 AFFIRM data for subcutaneous Skyrizi (risankizumab) in Crohn’s disease was released and coincided with a notable AbbVie stock drop, suggesting investor concern about the results.
Perianal fistulizing Crohn's disease causes major quality-of-life problems and is often hard to treat. This trial tests risankizumab in people who did not respond to or could not tolerate other standard therapies, and it...
This OLE study follows patients who lost response to ustekinumab every-8-week dosing and evaluates whether increasing to every-4-week dosing maintains efficacy and safety long-term. That question is directly relevant to...
Long-term Phase 3 extension data suggest guselkumab (Tremfya) may provide sustained clinical and endoscopic remission for some adults with moderate-to-severe Crohn's disease, which could expand treatment options for...
Cure8 could only read part of this source from marketscreener.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Fistula and Research and clinical trials.
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from seekingalpha.com.
Long-term control of symptoms and intestinal inflammation is a major need in Crohn's disease. Three-year data showing sustained clinical and endoscopic remission and high rates of steroid-free remission could be...
Long-term (3-year) data on a biologic for Crohn's disease may indicate how durable treatment benefits and steroid-free remission can be for people considering or already on biologic therapy.
Perianal fistulas are a common and debilitating complication of Crohn’s disease that often need medical and surgical care. A Phase 3 trial reporting improved fistula remission with an IL-23–targeting therapy could offer...
Patients with PsA and clinicians choosing long‑term biologic therapy may care about both durability of PsA control and safety signals for related inflammatory conditions like IBD and uveitis. This analysis reports...
New Phase 3 and long‑term analyses presented at ACG 2026 report that risankizumab and upadacitinib showed disease control in patients with moderate‑to‑severe IBD, including difficult‑to‑treat Crohn’s disease. These...
This study suggests mirikizumab can maintain endoscopic and symptomatic improvements for up to two years in many patients with Crohn’s disease, and that IV reinduction can recover response in a subset of 1-year...
Bowel urgency is a common, distressing symptom in ulcerative colitis that matters for quality of life. This analysis indicates vedolizumab may reduce urgency and that early improvement is linked to better clinical and...
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Ulcerative colitis, Inflammatory bowel disease, and Upadacitinib. The original article is from Clinical Gastroenterology and...
